Plain-English translation of NCT06427694 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether a medication called (a low-dose form of interleukin-2) can help your heart recover after a heart attack by boosting protective immune cells. These special immune cells may reduce the dangerous inflammation in your arteries that caused the blockage in the first place. The medication has shown promise in an earlier study, and now researchers want to confirm whether it actually improves heart function and prevents future problems.
After a heart attack, your immune system continues to cause inflammation in your arteries, which can lead to more blockages and damage. People who have had heart attacks have fewer protective immune cells than others, and boosting these cells might prevent future heart problems.
You likely qualify if…
You likely don't qualify if…
This is a follow-up study for people who already completed the earlier IVORY trial. Researchers will review your medical records and health outcomes from when you finished the first study. If you passed away, researchers may still include information from your records to learn from your experience. The main goal is to understand the longer-term effects of the treatment you received and whether it helped prevent future heart problems.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United Kingdom